Improving treatment outcomes by understanding cytogenetics in myelodysplastic
Aristotle Giagounidis
Medizinische Klinik II St. Johannes Hospital Duisburg, Germany
Myelodysplastic syndromes (MDS) represent a heterogeneous group of blood disorders that are generally characterised by refractory anaemia (RA) or cytopenia, hypercellular bone marrow, and ineffective haematopoiesis. Most cases of MDS have an increased risk of transformation to acute myeloid leukaemia (AML). The prognosis of patients with MDS varies considerably, reflecting the underlying heterogeneity within this class of disorders.
[>Read full article in PDF]